| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c7b6e1b37598ac297cc9f9c006fdeee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d245ebb80cf75fe729644abdb113abc1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed266051d5fbde6af8088f11f42dd6b1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-45 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-3804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-3839
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-721
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-721
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737 |
| filingDate |
2010-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3adf13a37731875aed1f729f1a22aead
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_149033cc142aeb290928850c3707fc65 |
| publicationDate |
2014-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8906884-B2 |
| titleOfInvention |
Method of treating graft-rejection using dextran sulfate |
| abstract |
The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10730960-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9446066-B2 |
| priorityDate |
2002-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |